Certara's $12 Price Target Implies 57.7% Upside; Leerink Upgrades
60% of analysts remain bullish on Certara, with a consensus price target of $12 implying 57.7% upside potential. KeyBanc cut its target from $13 to $12 but maintained an Overweight rating, while Leerink upgraded the stock to Outperform citing biosimulation leadership and growth momentum.
1. Analyst Consensus and Upside
As of February 5, 2026, 60% of analysts hold a bullish view on Certara, reflected in a consensus price target of $12.00 that suggests 57.7% upside from recent levels. This sentiment underscores confidence in the company’s biosimulation services and anticipated market inflection in the year ahead.
2. KeyBanc's Revised Outlook
On January 8, KeyBanc lowered its price target for Certara from $13 to $12 while reaffirming an Overweight rating, highlighting fundamental momentum in Healthcare IT despite competitive and regulatory headwinds. The firm expects valuation multiples to recover as sector volatility subsides.
3. Leerink's Upgrade Rationale
Leerink raised Certara from Market Perform to Outperform on January 6, retaining a $13 price target due to the company’s leadership position in the broad-based biosimulation market. The upgrade follows a late-2025 pullback in services bookings and biopharma budget delays, which Leerink views as an overreaction ahead of projected growth acceleration in 2026.